Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com -- AIM ImmunoTech (OTC:AIMID) Inc. (NYSE American:AIM) stock plummeted 51.8% after the company announced the pricing of a public offering expected to raise approximately $8 million in gross proceeds.
The offering consists of 2 million shares of common stock (or pre-funded warrants in lieu thereof), along with Class E and Class F warrants to purchase up to an additional 4 million shares. The combined public offering price was set at $4.00 per share (or $3.999 per pre-funded warrant) with accompanying warrants.
Both warrant classes will have an exercise price of $4.00 per share and will be exercisable immediately upon issuance. The Class E warrants will expire five years from issuance, while the Class F warrants will expire after 18 months.
Maxim Group LLC is serving as the sole placement agent for the offering, which is expected to close around July 30, 2025, subject to customary closing conditions.
The securities are being offered through a registration statement on Form S-1 that was declared effective by the Securities and Exchange Commission on July 28, 2025.
The significant stock decline reflects typical market reaction to public offerings, which often dilute existing shareholders’ ownership stakes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.